https://mindmedicinelaw.com/briefing/ketamine-s-impact-on-ovarian-function-in-depression-models-20260808-30501The Psychedelic Journalen2026-08-09T15:06:41.275280+00:00Ketamine's Impact on Ovarian Function in Depression Modelsketamine, ovarian function, depression, ferroptosis, reproductive health, mental health, oocyte quality, corticosterone model, GPX4, female reproductive disordershttps://mindmedicinelaw.com/briefing/challenges-in-rural-drug-treatment-in-australia-20260807-30495The Psychedelic Journalen2026-08-09T15:06:54.377549+00:00Challenges in Rural Drug Treatment in Australiarural drug treatment, Australia, integrated care models, culturally responsive services, workforce shortages, telehealth, Aboriginal clients, healthcare access, social determinants, public healthhttps://mindmedicinelaw.com/briefing/psilocybin-in-nicotine-addiction-therapy-neuropsychology-insights-20260807-30462The Psychedelic Journalen2026-08-09T15:05:45.748360+00:00Psilocybin in Nicotine Addiction Therapy: Neuropsychology Insightspsilocybin, nicotine addiction, serotonin receptors, neuroplasticity, clinical trials, psychedelic therapy, smoking cessation, Default Mode Network, mental health, substance dependencehttps://mindmedicinelaw.com/briefing/psilocybin-s-potential-for-phantom-limb-pain-new-insights-20260807-30394The Psychedelic Journalen2026-08-08T22:05:43.894924+00:00Psilocybin's Potential for Phantom Limb Pain: New Insightspsilocybin, phantom limb pain, psychedelic research, clinical trials, pain management, neuroscience, public health, regulatory considerations, therapeutic applications, mental health disordershttps://mindmedicinelaw.com/briefing/psilocybin-s-potential-in-cluster-headache-treatment-20260807-30167The Psychedelic Journalen2026-08-08T22:05:36.856596+00:00Psilocybin's Potential in Cluster Headache Treatmentpsilocybin, cluster headaches, psychedelic therapy, clinical trials, headache disorders, treatment efficacy, safety profile, neuroscience, patient care, therapeutic potentialhttps://mindmedicinelaw.com/briefing/psilocybin-trial-expands-in-connecticut-for-mental-health-20260807-30134The Psychedelic Journalen2026-08-08T22:05:25.889076+00:00Psilocybin Trial Expands in Connecticut for Mental Healthpsilocybin trial, connecticut research, mental health treatment, psychedelic therapy, clinical trials, neuroscience, public health, complex mental conditions, veterans and first responders, psychedelic policyhttps://mindmedicinelaw.com/briefing/psilocybin-and-motor-function-insights-from-phase-1-study-20260807-30166The Psychedelic Journalen2026-08-08T15:08:34.292235+00:00Psilocybin and Motor Function: Insights from Phase 1 Studypsilocybin, motor function, phase 1 study, psychedelic-assisted therapy, clinical trials, dose management, adverse events, physical rehabilitation, neuroscience, public healthhttps://mindmedicinelaw.com/briefing/long-term-safety-of-ketamine-and-esketamine-in-trd-20260807-30176The Psychedelic Journalen2026-08-08T15:07:53.291636+00:00Long-term Safety of Ketamine and Esketamine in TRDketamine, esketamine, treatment-resistant depression, long-term safety, systematic review, organ toxicity, iatrogenic addiction, clinical trials, neurocognitive effectshttps://mindmedicinelaw.com/briefing/long-term-safety-of-ketamine-and-esketamine-for-trd-20260807-30177The Psychedelic Journalen2026-08-08T15:07:42.668779+00:00Long-term Safety of Ketamine and Esketamine for TRDketamine, esketamine, treatment-resistant depression, long-term safety, clinical trials, neurocognitive effects, iatrogenic addiction, standardized protocols, systematic review, psychiatric treatmenthttps://mindmedicinelaw.com/briefing/comparative-efficacy-of-ect-and-ketamine-in-trd-20260806-30179The Psychedelic Journalen2026-08-09T15:06:12.741994+00:00Comparative Efficacy of ECT and Ketamine in TRDtreatment-resistant depression, ketamine, electroconvulsive therapy, neuroplasticity, clinical phenotypes, suicidal ideation, neurobiological adaptations, maintenance protocols, psychotic depression, glutamatergic systemhttps://mindmedicinelaw.com/briefing/public-health-priorities-for-psychedelics-in-the-u-s-20260806-30136The Psychedelic Journalen2026-08-09T15:05:58.387492+00:00Public Health Priorities for Psychedelics in the U.S.psychedelic research, public health preparedness, education and prevention, workforce development, strategic information, data analysis, therapeutic potential, risk management, behavioral health, policy decision-makinghttps://mindmedicinelaw.com/briefing/fragmented-pat-assessment-methods-integration-needed-20260806-30135The Psychedelic Journalen2026-08-08T22:06:05.852961+00:00Fragmented PAT Assessment Methods: Integration Neededpsychedelic-assisted therapy, PAT assessment methodologies, clinical trials, safety monitoring, evaluation models, therapeutic practices, methodological integration, psychedelic research, clinical intervention frameworks, existential outcomeshttps://mindmedicinelaw.com/briefing/psychedelics-and-neurodevelopmental-disorders-emerging-research-20260806-30139The Psychedelic Journalen2026-08-08T22:05:58.294227+00:00Psychedelics and Neurodevelopmental Disorders: Emerging Researchpsychedelics, neurodevelopmental disorders, LSD, psilocybin, ketamine, neuroplasticity, clinical trials, serotonergic receptors, NMDA receptor, cognitive deficitshttps://mindmedicinelaw.com/briefing/mystical-experiences-in-mdma-therapy-for-ptsd-new-insights-20260806-30154The Psychedelic Journalen2026-08-08T22:05:51.250392+00:00Mystical Experiences in MDMA Therapy for PTSD: New InsightsMDMA-assisted therapy, PTSD treatment, mystical experiences, positive mood, psychedelic research, clinical trials, mental health, therapeutic frameworks, dosing strategies, psychedelic therapyhttps://mindmedicinelaw.com/briefing/psilocybin-trial-for-depression-in-nhs-promising-results-20260806-30138The Psychedelic Journalen2026-08-08T15:08:23.176532+00:00Psilocybin Trial for Depression in NHS: Promising Resultspsilocybin, NHS, treatment-resistant depression, clinical trial, psychedelic therapy, mental health, public healthcare, depression treatment, psilocybin efficacy, adverse eventshttps://mindmedicinelaw.com/briefing/well-being-as-primary-endpoint-in-psychedelic-trials-20260806-30137The Psychedelic Journalen2026-08-08T15:08:10.982306+00:00Well-being as Primary Endpoint in Psychedelic Trialspsychedelic therapy, clinical trials, well-being endpoint, FDA policy, psychiatric evaluations, Delphi method, regulatory frameworks, therapeutic outcomes, symptom reduction, psychedelic researchhttps://mindmedicinelaw.com/briefing/engineered-mice-advance-psychedelic-research-in-neuroscience-20260806-30168The Psychedelic Journalen2026-08-08T15:08:03.909206+00:00Engineered Mice Advance Psychedelic Research in Neuroscienceengineered mice, psychedelic research, 5-HT2A receptor, neuropsychiatric disorders, LSD and psilocybin, molecular actions, behavioral studies, electrophysiology, drug development, ethical considerationshttps://mindmedicinelaw.com/briefing/psilocybin-induced-synaptic-plasticity-in-mice-implications-for-antidepressant-r-20260805-30172The Psychedelic Journalen2026-08-09T15:06:26.887543+00:00Psilocybin-Induced Synaptic Plasticity in Mice: Implications for Antidepressant Researchpsilocybin, synaptic plasticity, antidepressant research, neuroplasticity, 5-HT 2A receptor, clinical trials, serotonin receptors, mice study, brain regions, therapeutic strategieshttps://mindmedicinelaw.com/briefing/psychedelic-enhanced-fear-extinction-rodent-study-insights-20260803-30081The Psychedelic Journalen2026-08-07T22:05:56.939067+00:00Psychedelic-Enhanced Fear Extinction: Rodent Study Insightspsychedelic research, fear extinction, rodent models, dose-effect patterns, anxiety disorders, clinical trials, psychedelic-assisted therapy, therapeutic applicationshttps://mindmedicinelaw.com/briefing/psilocybin-s-role-in-addressing-cancer-fear-new-study-insights-20260801-30070The Psychedelic Journalen2026-08-07T22:05:46.563402+00:00Psilocybin's Role in Addressing Cancer Fear: New Study Insightspsilocybin, cancer recurrence, psychedelic therapy, mental health, clinical guidelines, patient care, serotonin receptors, oncology, regulatory frameworks, psychological distress